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(range: 15 to 50 months). The unit of randomisation was the patient. No loss to follow up was reported. Blinding was applied in the assessment of patients' outcomes: data on ejection fractions were analysed by nuclear medicine specialists blinded to the clinical data.
Analysis of effectiveness
The analysis was based on intention to treat. The primary health outcomes used were mortality rate (cardiac related), fatal and non-fatal recurrent myocardial infarction and left ventricular ejection fraction, this last outcome being measured using a multiple-gated equilibrium method after the in vivo labelling of red cells with 99mm-Tcpertechnetate using a gamma camera with a low energy, all purpose, parallel-hole colimator. The global ejection fraction was calculated by a computer using the PAGE program. Groups were shown comparable with respect to general characteristics and prognostic features (history of infarctions).
Effectiveness results
Seven patients (5%) randomised to the intervention group died from a cardiac cause. Seventeen patients (11.4%) randomised to streptokinase died for the same reason, (p=0.03). The rate of recurrent myocardial infarction was 3.3% and 19.5%, respectively, (p<0.0001). The relative risk of the combination of cardiac death and non-fatal reinfarction of streptokinase patients compared to angioplasty patients was 4.3 (95% CI: 2.2 -8.3). The left ventricular ejection fraction was calculated twice (at discharge and during follow up), with 98% of survivors being assessed on the first occasion and 95% on the second. The ejection fractions were 48 (+/-12%) and43 (+/-13%), in the same order as before and with p=0.0025 (no significant differences were found between measured ejection fractions, for either group, between the first and second times of measurement).
Clinical conclusions
Patency of the infarct-related coronary artery was strongly related to clinical outcome and this explains the improved clinical outcome after angioplasty compared to thrombolytic therapy. In addition, the presence of multi-vessel disease, a history of previous myocardial infarction and the location of the infarction were important determinants of clinical outcome.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic study, and only separate clinical outcomes were reported.
Direct costs
Costs were not discounted and quantities were not reported separately from the costs, although cost items were reported separately. The costs measured were operating costs (hospital days, diagnostic or therapeutic procedures and medications) and costs of follow up assessment. The boundary adopted was not explicitly specified. The estimation of (unit) costs was based on the institutions' own standard and average prices. The source for unit costs was the hospital administration data. 1992 prices were used. There was an adjustment to costs in order to correct for the increased costs of procedures during the night or the weekend.
Statistical analysis of costs
Differences between group means were tested by a two tailed Student's t test.
